Citigroup
RPTX

Citigroup’s Repare Therapeutics RPTX Stock Holding History

Citigroup’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,395
Closed -$8.24K – 5931
2024
Q3 		$8.24K Buy
+2,395
New +$7.88K ﹤0.01% 5310
2024
Q2 		– Sell
-34
Closed -$160 – 5747
2024
Q1 		$160 Hold
34
– – ﹤0.01% 5487
2023
Q4 		$248 Sell
34
-523
-94% -$2.93K ﹤0.01% 5527
2023
Q3 		$6.73K Sell
557
-636
-53% -$6.56K ﹤0.01% 4652
2023
Q2 		$12.6K Buy
1,193
+238
+25% +$2.45K ﹤0.01% 5033
2023
Q1 		$9.4K Sell
955
-48
-5% -$551 ﹤0.01% 4758
2022
Q4 		$14.8K Buy
1,003
+42
+4% +$628 ﹤0.01% 4709
2022
Q3 		$12K Sell
961
-136
-12% -$1.75K ﹤0.01% 4933
2022
Q2 		$15K Sell
1,097
-15,059
-93% -$177K ﹤0.01% 5155
2022
Q1 		$230K Sell
16,156
-4,031
-20% -$59.8K ﹤0.01% 4010
2021
Q4 		$426K Sell
20,187
-5,118
-20% -$121K ﹤0.01% 3906
2021
Q3 		$664K Sell
25,305
-2,579
-9% -$83.3K ﹤0.01% 3421
2021
Q2 		$869K Buy
27,884
+27,086
+3,394% +$887K ﹤0.01% 3337
2021
Q1 		$24K Sell
798
-422
-35% -$14.3K ﹤0.01% 5148
2020
Q4 		$42K Buy
+1,220
New +$36.5K ﹤0.01% 6172

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citigroup's RPTX Position: Q4 2024 in Review

Citigroup sold out of Repare Therapeutics (RPTX) in Q4 2024, closing a stake of 2,395 shares — an estimated $8.24K sold.

Citigroup first reported a position in RPTX in Q4 2020 and held it in 15 quarters. The position peaked at $869K in Q2 2021. 54 funds tracked by Wall St. Rank hold RPTX as of Q4 2024.

  • Citigroup reported no remaining Repare Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Citigroup sold 2,395 Repare Therapeutics shares in Q4 2024, an estimated $8.24K.
  • Citigroup first reported a position in Repare Therapeutics in Q4 2020 and held it in 15 quarters.
  • Citigroup's Repare Therapeutics position peaked at $869K in Q2 2021.
  • 54 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2024.

Based on Citigroup's 13F filing for Q4 2024, filed 12 Feb 2025.